“Eloquest Healthcare is known for delivering innovative solutions that improve the standard of care with an emphasis on infection prevention and enhanced patient satisfaction, making them a perfect partner for Access Vascular,” said James Biggins, CEO at Access Vascular Inc. “Our mission is to eliminate complications like catheter thrombosis, phlebitis and resulting infections, thereby improving the efficacy of vascular access procedures. This partnership will help us carry that mission further and faster.”

Data presented at the AVA Annual Scientific Meeting shows impactful reductions in occlusions, DVT, and phlebitis using materials that mimic the body’s chemistry

Access Vascular, Inc. (AVI), a company addressing the most common and costly vascular access complications through its advanced biomaterial platform, today shared initial findings from two new clinical studies that demonstrate a significant reduction in complications when using AVI’s consistently hydrophilic materials for peripherally inserted central catheters (PICC) and midline catheters.

Despite incremental changes to catheter design and placement techniques, catheter related complication rates remain unacceptably high and range between 30% and 34%1,2. Complications such as catheter related thrombosis, phlebitis and infections impact patient safety, increase total medical costs, and create frustration for clinicians.

Access Vascular, Inc., a company addressing the most common and costly venous access complications, today announced it has closed on a Series B round of financing. TVM Capital Life Science led the round with a $15 million commitment, with existing investors also participating.

Access Vascular, Inc. today announced FDA clearance of its HydroMID™ midline catheter. HydroMID, which is made of Access Vascular’s proprietary biomaterial that has been shown to reduce thrombus accumulation by up to 97 percent when compared to standard polyurethane catheters,1 is the second device in its planned portfolio to obtain clearance.

Access Vascular has developed a proprietary biomaterial platform that is both hydrophilic and lubricious, and has incorporated this material into two commercially-available venous access devices, the HydroPICC® Peripherally Inserted Central Catheter and HydroMID™ Midline Catheter. In vitro studies have shown that this biomaterial technology results in an average of 97% less thrombus accumulation on its surface compared to a standard polyurethane catheter.*

Access Vascular, Inc. today announced it has received FDA clearance for the second generation of its HydroPICCTM peripherally inserted central catheter (PICC), which has demonstrated an average of 97% less thrombus accumulation on its surface compared to a standard polyurethane catheter1.

Access Vascular, a medical device company developing the next generation of intravenous devices from novel biomaterials designed to minimize the risk of bloodstream infection, catheter thrombosis, and vein trauma, announced $6M in new funding from new and existing investors. With this new round, Access Vascular is poised to launch the next generation of its FDA-cleared HydroPICC device, initiate the company's first post-market registry study, and expedite new product development.

Access Vascular, Inc. has been awarded a group purchasing agreement for a Breakthrough Technology contract with Premier. Effective September 1, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the HydroPICC™ peripherally inserted central catheter which is indicated for reduced thrombus accumulation. In benchtop studies, HydroPICC has demonstrated a 97% reduction in thrombus accumulation compared to traditional polyurethane PICCs.

Access Vascular is pleased to announce the publication of head-to-head in vitro tip occlusion results comparing HydroPICC with the market leading catheter, PowerPICC (Becton Dickinson). In in vitro blood flow loop testing, HydroPICC exhibited a complete reduction in thrombotic occlusion rate when compared to the PowerPICC catheter.

Access Vascular had the opportunity to host Dr. Jeffrey Chick and Dr. Arun Jagannathan at the company’s booth at the Society of Interventional Radiology 2019 conference for an engaging discussion on difficult venous access. The podcast was hosted by BackTable podcast, a premier source for information on tools and techniques for interventional radiologists.

Access Vascular has published the results of in-vitro and in-vivo studies of HydroPICC. HydroPICC showed an an average of 97% less thrombus accumulation on its surface (based on platelet count)* compared to a standard polyurethane catheter.

MassDevice: Access Vascular, a medical device company reinventing venous access using proprietary material technology designed to reduce thrombus accumulation, announced today that the Company has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its lead product.